HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models.

SCD50 X-ray irradiation lutetium-177 paraganglioma radionuclide therapy radioresistance spheroid control dose spheroid re-growth

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Jan 2021
Historique:
received: 16 12 2020
revised: 15 01 2021
accepted: 18 01 2021
entrez: 26 1 2021
pubmed: 27 1 2021
medline: 27 1 2021
Statut: epublish

Résumé

Pheochromocytomas and paragangliomas (PCCs/PGLs) are rare neuroendocrine tumors arising from chromaffin tissue located in the adrenal or ganglia of the sympathetic or parasympathetic nervous system. The treatment of non-resectable or metastatic PCCs/PGLs is still limited to palliative measures, including somatostatin type 2 receptor radionuclide therapy with [

Identifiants

pubmed: 33494435
pii: cancers13030385
doi: 10.3390/cancers13030385
pmc: PMC7865577
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Collaborative Research Center Transregio 205 "The Adrenal: Central Relay in Health and Disease"
ID : CRC/TRR 205/1
Organisme : Paradifference Foundation
ID : Consortium for Personalized Targeted Therapy for SDHB-mutated Metastatic PCCs/PGLs

Références

Cancers (Basel). 2020 Sep 25;12(10):
pubmed: 32993034
Endocr Relat Cancer. 2016 Dec;23(12):899-908
pubmed: 27679736
Phys Med Biol. 2016 Oct 7;61(19):6935-6952
pubmed: 27617585
Nat Rev Cancer. 2011 Dec 15;12(1):9-22
pubmed: 22169972
Int J Cancer. 2014 Aug 15;135(4):968-80
pubmed: 24615356
Endocrinology. 2014 Nov;155(11):4149-56
pubmed: 25137029
APMIS. 2004 Sep;112(9):551-9
pubmed: 15601303
Int J Mol Sci. 2015 Dec 28;17(1):
pubmed: 26729091
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51
pubmed: 22005114
Cancers (Basel). 2011 Oct 11;3(4):3838-55
pubmed: 24213114
Neuroendocrinology. 2019;109(4):287-298
pubmed: 30856620
Int J Mol Sci. 2016 May 16;17(5):
pubmed: 27196891
J Nucl Med. 2005 Dec;46(12):2112-6
pubmed: 16330578
Mol Cell. 2008 May 23;30(4):393-402
pubmed: 18498744
Cancers (Basel). 2019 Apr 28;11(5):
pubmed: 31035382
Cancer Biother Radiopharm. 2005 Feb;20(1):47-51
pubmed: 15778580
Nuklearmedizin. 2009;48(3):120-6
pubmed: 19322501
Oncotarget. 2017 Apr 11;8(15):25756-25782
pubmed: 28187001
Nat Rev Cancer. 2014 Feb;14(2):108-19
pubmed: 24442145
J Exp Med. 1973 Oct 1;138(4):745-53
pubmed: 4744009
J Natl Cancer Inst. 2013 Sep 4;105(17):1270-83
pubmed: 23940289
Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):259-68
pubmed: 8420873
Br J Cancer. 1992 Dec;66(6):1048-52
pubmed: 1457344
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):307-17
pubmed: 9607346
Theranostics. 2016 Mar 10;6(5):650-65
pubmed: 27022413
Cell Death Dis. 2015 Jan 15;6:e1600
pubmed: 25590810
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
Nucl Med Mol Imaging. 2019 Jun;53(3):223-230
pubmed: 31231443
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3278-3287
pubmed: 28605448
Horm Metab Res. 2012 May;44(5):411-4
pubmed: 22566197
Endocr Relat Cancer. 2020 Nov;27(11):625-640
pubmed: 33112842
Trends Endocrinol Metab. 2017 Nov;28(11):807-817
pubmed: 28867159
EJNMMI Phys. 2018 Sep 3;5(1):18
pubmed: 30175390
Hum Mol Genet. 2011 Oct 15;20(20):3974-85
pubmed: 21784903
J Cancer Res Clin Oncol. 1987;113(2):101-22
pubmed: 3549738
Endocr Relat Cancer. 2004 Sep;11(3):423-36
pubmed: 15369446
Endocr Pathol. 2012 Mar;23(1):34-42
pubmed: 22183643
Cancer Cell. 2017 Feb 13;31(2):181-193
pubmed: 28162975
Chem Rev. 2015 Apr 22;115(8):2934-74
pubmed: 25865818
Eur J Endocrinol. 2019 Jul;181(1):45-53
pubmed: 31067510
Toxicol Appl Pharmacol. 2007 Aug 15;223(1):86-98
pubmed: 17602717
Pharmacol Ther. 2016 Aug;164:152-69
pubmed: 27139518
Am J Surg. 2011 May;201(5):700-8
pubmed: 20870212
Pathologe. 2003 Jul;24(4):280-6
pubmed: 14513275
Mol Endocrinol. 2010 Dec;24(12):2382-91
pubmed: 20980436
J Biol Chem. 2004 Apr 9;279(15):14871-8
pubmed: 14744852
EJNMMI Res. 2019 Feb 6;9(1):13
pubmed: 30725219
Int J Cancer. 2014 Nov 1;135(9):2054-64
pubmed: 24676840
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Nat Rev Cancer. 2008 Dec;8(12):967-75
pubmed: 18987634
Antimicrob Agents Chemother. 1999 May;43(5):1003-12
pubmed: 10223907
Q J Nucl Med Mol Imaging. 2013 Jun;57(2):153-60
pubmed: 23598685

Auteurs

Verena Seifert (V)

Department of Radiopharmaceutical and Chemical Biology, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.
Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, 01069 Dresden, Germany.

Susan Richter (S)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus at Technische Universität Dresden, 01307 Dresden, Germany.

Nicole Bechmann (N)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus at Technische Universität Dresden, 01307 Dresden, Germany.
Department of Internal Medicine III, University Hospital Carl Gustav Carus at Technische Universität Dresden, 01307 Dresden, Germany.
Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany.
German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany.

Michael Bachmann (M)

Department of Radioimmunology, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.

Christian G Ziegler (CG)

Department of Internal Medicine III, University Hospital Carl Gustav Carus at Technische Universität Dresden, 01307 Dresden, Germany.

Jens Pietzsch (J)

Department of Radiopharmaceutical and Chemical Biology, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.
Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, 01069 Dresden, Germany.

Martin Ullrich (M)

Department of Radiopharmaceutical and Chemical Biology, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.

Classifications MeSH